Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct
- PMID: 33447823
- PMCID: PMC7798465
- DOI: 10.1016/j.bioflm.2020.100039
Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct
Abstract
Biofilms contribute significantly to the chronicity and recurrence of bacterial diseases due to the fact that biofilm-resident bacteria are highly recalcitrant to killing by host immune effectors and antibiotics. Thus, antibody-mediated release of bacteria from biofilm residence into the surrounding milieu supports a powerful strategy to resolve otherwise difficult-to-treat biofilm-associated diseases. In our prior work, we revealed that antibodies directed against two unique determinants of nontypeable Haemophilus influenzae (NTHI) [e.g. the Type IV pilus (T4P) or a bacterial DNABII DNA-binding protein, a species-independent target that provides structural integrity to bacterial biofilms] release biofilm-resident bacteria via discrete mechanisms. Herein, we now show that the phenotype of the resultant newly released (or NRel) NTHI is dependent upon the specific mechanism of release. We used flow cytometry, proteomic profiles, and targeted transcriptomics to demonstrate that the two NRel populations were significantly different not only from planktonically grown NTHI, but importantly, from each other despite genetic identity. Moreover, each NRel population had a distinct, significantly increased susceptibility to killing by either a sulfonamide or β-lactam antibiotic compared to planktonic NTHI, an observation consistent with their individual proteomes and further supported by relative differences in targeted gene expression. The distinct phenotypes of NTHI released from biofilms by antibodies directed against specific epitopes of T4P or DNABII binding proteins provide new opportunities to develop targeted therapeutic strategies for biofilm eradication and disease resolution.
Keywords: Antibiotic; Chronic infection; Dispersal; Disruption; Proteomics; Quorum sensing.
© 2020 The Author(s).
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.O.B. and S.D.G. are the inventors of technology related to the DNABII proteins, rights to which have been licensed to Clarametyx Biosciences, Inc. L.O.B. is an inventor of technology related to PilA-derived immunogens that is licensed to GlaxoSmithKline Biologicals. E.M.M., C.P.A., J.R.B., L.A.N., and Y.Z. have no interests to declare.
Figures
References
-
- Cardines R., Giufre M., Pompilio A., Fiscarelli E., Ricciotti G., Di Bonaventura G., Cerquetti M. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol. 2012;302:45–52. doi: 10.1016/j.ijmm.2011.08.003. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
